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Introduction
Malaria is one of the most important causes of parasitic infection and death in the world. A WHO report estimates in 189-327 millions the cases of malaria and in about 1 million the associated deaths, the major part of them occurring in children living in sub-Saharan Africa [1] . There is an increasing need both of new antimalarial drugs and of improvements of those already in use, in particular of agents active against the infection due to Plasmodium falciparum, which is the main agent of severe malaria.
Nitric oxide (NO) is a physiological messenger with multiple actions. In the cardiovascular system it is involved in maintaining the micro-and macro-vascular homeostasis [2] . In particular, it induces vasodilation and inhibits platelet aggregation through a cyclic GMP (cGMP) dependent mechanism and it modulates the expression of the cell-adhesion molecules (CAMs) on endothelial cells. In the central nervous system, it plays complex roles in learning, memory formation and neurotransmitters release, while in the peripheral nervous system behaves as a neurotransmitter at the ends of nonadrenergic, non-cholinergic nerves controlling a number of gastrointestinal, respiratory and genitourinary functions [3] . In the innate immune system NO is one of the final effector molecules against pathogens of different origin. It regulates other immunological functions, as well, including T-and B-cell proliferation, leukocytes rolling and cytokines production [4] . Finally, NO seems to play an important role in the pathogenesis of P falciparum malaria both as antiplasmodial agent and regulator of the immune response to the parasite. This suggested the hypothesis that derivatives of NO could be effective antimalarial agents [5] . Indeed, it was found that some NO-donors display in vitro toxic action against P. falciparum [6] [7] [8] .
Severe falciparum malaria, including cerebral malaria (CM), is associated with tissue ischemia related to cytoadherence of parasitized erythrocytes to microvascular endothelium. CM has been reported to be associated to low NO bioavailability in the vasculature [9, 10] . This is due to both an increased scavenging of NO in the blood, caused by the high concentration of free oxyhaemoglobin (HbO 2+ ) from the haemolysis of parasitized red blood cells and to hypoargininemia. Administration of exogenous NO to the murine model of CM induced by P.berghei ANKA (PbA) restored signalling in the brain, decreased proinflammatory biomarkers in the blood, and markedly reduced vascular leak and petechial hemorrhages in the brain [10a] . Moreover, a significant improvement of CM has been observed in patients after infusion of l-arginine demonstrating that the NO pathway can be targeted for adjunctive treatment in falciparum malaria [10b] . Amodiaquine (AQ, Chart 1 ) is an established antimalarial drug recently reintroduced in the World Health Organisation Model List of Essential Medicines [11, 12] .
As development of our previous work aimed at designing new NO-donor multifunctional drugs [13] , we now report a study concerning the synthesis, the dissociation constants and the in vitro anti P. falciparum activity of new NO-donor amodiaquine derivatives (NO-AQ) containing either furoxan (1,2,5-oxadiazole 2-oxide) or nitrooxy (-ONO 2 ) NO-donor substructures. The capacity of NO-AQ of relaxing rat aorta strips with a NO-dependent mechanism, and in vivo preliminary data which seem to confirm their potential utility in the treatment of CM, are also discussed.
Insert Chart 1
Results and discussion

Chemistry
Derivatives 3, 4, 7, 12-15, bearing nitrooxy functionalities and a primary or a secondary amino group, used for building the final nitrooxy substituted compounds, were synthesised following the pathways described in Scheme 1. Compounds 3 and 4 were synthesised by nitration with fuming nitric acid of the related commercially available amino alcohols 1 and 2. For the synthesis of 6-(ethylamino)hexan-1-ol (6) the commercially available 6-chlorohexanol (5) was treated with ethylamine and then with HCl to give 5aHCl. The hydrochloride was converted into the corresponding free base by ion-exchange chromatography on cationic resin (Amberlite IRA-400).
This base was transformed into 7HNO 3 by treatment with fuming nitric acid in 34% overall yield.
For the synthesis of piperidino-and piperazino-based nitrooxy derivatives, the commercially available piperidino or piperazino alcohols 8-11 were nitrated following the usual procedure to afford compounds 12-15 in 60-67% yields.
Insert Scheme 1
The synthesis of 6-(ethylamino)hexane-1,1-diyl dinitrate (26) The final AQ derivatives 37, 40 bearing furoxan moieties were synthesised starting from 27 (Scheme 4). To obtain the phenylfuroxanyl substituted compound 37 the chloromethyl substituted intermediate 27 was transformed into hydroxyamodiaquine 36 by treatment with 2-ethylamino ethanol in acetonitrile. This last compound was treated with 3-phenyl-4-benzenesulfonyl furoxan and 50% (w/w) NaOH, under nitrogen atmosphere in distilled THF/DMF mixture, to give the desired product. Owing to extensive decomposition of the reaction mixture, it was impossible to obtain 40 in the same way. This product was obtained by reacting 27 with N-ethyl-2-((3-phenylsulfonyl)furoxan-4-yl)oxy)ethanamine 39 that, in its turn, was obtained by NaOH-mediated reaction of 2-(ethylamino)ethanol with bis-benzenesulfonyl furoxan 38. The proposed structure of 39 was confirmed by its 13 C-NMR spectrum, which is typical of a 4-alkoxy-3-phenylsulfonyl substituted furoxan [16] .
Insert Scheme 4
Dissociation constants determination
Potentiometric titrations of the final amodiaquine derivatives were performed with a Sirius GLpK a automated potentiometric system. The titrations were carried out in water using methanol in different ratios as co-solvent; the aqueous pK a s were determined by extrapolation to 0% methanol according to Yasuda-Shedlovsky procedure (see experimental). The pK a values are listed in Table 1 .
Using AQ as reference compound (pK a1 = 8.47, lateral chain nitrogen; pK a2 =7.42, 4-aminoquinoline centre) [17] it is reasonable to assign in the analogues No activity in the nM range was observed for the simple nitric acid esters 3, 7, 12-15, used to prepare the nitrooxysubstituted NO-AQ, as well as for the two simple furoxans A, B (Table 2) structurally similar to the furoxan moieties present in 37 and 40 respectively. These results indicate that the contribution of NO to the antiplasmodial properties of NO-AQ is, if any, secondary to that of the lead structure.
Vasodilator activity
All the NO-AQ products described in this work were able to relax rat aorta strips precontracted with phenylephrine. The vasodilator potencies, expressed as EC 50 , are reported in 1D ). Total parasite clearance with both compounds and AQ was achieved after 72 hours and three doses of treatment in mice that survived and no recrudescence was observed after a 5-day treatment regimen ( Figure 1C and 1D).
Conclusions
We have developed a new series of NO-AQ derivatives which are able to retain a high degree of activity in vitro against both CQ-S and CQ-R strains of P. falciparum. At least in vitro, the contribution of NO to the antiplasmodial properties of these products seems to be secondary to that of the lead. All the compounds are able, in different degree, to dilate pre-contracted rat aorta strips with a NO-dependent mechanism, and consequently they could be capable to help restoring the vascular homeostasis which is deeply compromised in CM. Indeed, low NO bioavailability plays a role in the pathogenesis of murine CM [10] , which is associated with cerebral microcirculatory dysfunction and vasoconstriction [18] . Treatment with an NO donor, 1-[N-(3-Aminopropyl)-N-(3-ammoniopropyl)]diazen-1-ium-1,2-diolate (DPTA-NO) largely prevents the neurological syndrome and this is associated with improved cerebral vascular responses [19] . We asked whether a hybrid compound endowed with antimalarial and NO activities could improve survival in mice with late stage CM, in comparison with its lead compound presenting antimalarial activity only. Our preliminary results with compounds 40 and 31 in the murine model of CM by P. berghei ANKA indeed showed a trend for increased survival of the animals treated with compound 40, which is a potent and fast NO-donor. It is remarkable that survival rates were increased three-fold, especially considering that mice left untreated at late stage of CM die in a few hours, and AQ by itself was highly ineffective at this stage. Earlier treatment and shorter intervals for drug administration may help to further improve the efficacy. The same trend for increased survival was not observed with compound 31, a milder NO-donor. Further in vivo studies are in progress to disclose the interesting potentialities of these products, and of other NO-donor antimalarial drugs, in the treatment of CM.
Experimental
Instrumentation and chemicals
Melting points were determined with a capillary apparatus Büchi B-540 or Büchi B-530 (uncorrected). Melting point with decomposition were determined after introduction of the sample at a temperature 10 °C lower than the melting point. A heating rate of 2 °C min -1 was used. within  0.4% of the theoretical. 3-phenyl-4-benzenesulfonyl furoxan [20] , 3 [21] , 27 [15] , 38 [22] , A, B [23] , were synthesised according to reported methods.
Chemistry
6-(ethylamino)hexan-1-ol (6)
6-chlorohexan-1-ol (5) 
N-ethyl-6-(nitrooxy)hexan-1-ammonium nitrate (7)
To 10 ml of fuming nitric acid at -15 °C, 0.55g (3.8 mmol) of 6 were added dropwise. The mixture was allowed to warm at room temperature and was kept under stirring for 24 h. The solution was then evaporated under reduced pressure and the residue was dropped in 100 ml of anhydrous Et 2 O at -15 °C. After 2 h at 0 °C the solvent was decanted off and the semisolid residue was triturated several times with fresh diethyl ether and was used without further purification. The product was characterized as free base which was obtained by extraction of a slurry of the semisolid with Na 2 CO 3 , with EtOAc. The organic phase was then washed with brine, dried over Na 2 SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with DCM/MeOH 5 % to afford 0.62 g of the desired product as a colorless oil (65 % The appropriate alcohol was added dropwise to 15 ml of fuming nitric acid at -15 °C. The mixture was allowed to warm at room temperature and was kept under stirring for 24 h. The solution was then evaporated under reduced pressure and the residue was dropped in 100 ml of anhydrous Et 2 O at -15 °C. After 2 h at 0 °C the solvent was decanted off and the semisolid residue was triturated several times with fresh diethyl ether to obtain an off-white solid (60-93% yields). 
N-ethyl-3-(nitrooxy)propan-1-ammonium nitrate (4).
H-NMR (DMSO-d
2-hex-5-enyl-1H-isoindole-1,3(2H)-dione (17).
5-hexen-1-ol 16 (10 g, 10 mmol) was converted to the corresponding methanesulfonate according to a reported procedure [26] . The crude product was then suspended in CH 3 CN with potassium phtalimide (1.5 eq) and a catalytic amount of potassium iodide. The mixture was refluxed for 72 h, then cooled and filtered on a sintered-glass funnel. The filtrate was purified by flash chromatography eluting with PE/EtOAc 10% to afford the desired product as a white solid (20 g, 86%) . Spectral data were consistent with the reported ones [27] . 1 
2-(5,6-dihydroxyhexyl)-1H-isoindole-1,3(2H)-dione (18).
To a solution of 5 g of 17 (22 mmol) in 200 ml of acetone cooled in an ice bath, a solution of KMnO 4 in 200 ml of water was added dropwise. After the addition was over the mixture was allowed to raise to room temperature and kept under stirring for further 3 h; the brownish solid was filtered off on a sintered glass funnel and the filtrate was concentrated under reduced pressure. The residue was taken up with 100 ml of water and extracted with EtOAc (6 x 50 ml). The organic extracts were washed with brine (1 x 100 ml), dried and the solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with 
2-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)butyl]-1H-isoindole-1,3(2H)-dione (19).
To 
4-(2,2-dimethyl-1,3-dioxolan-4-yl)butan-1-amine (20).
To a stirred solution of 19 (3 g;10 mmol) in 100 ml of distilled THF, hydrazine monohydrate (3.9 ml; 8 eq.) was added and the mixture was stirred under reflux for 24 h. After cooling the mixture was filtered on a sintered-glass funnel and the filtrate was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with DCM/MeOH 5%, DCM/MeOH 10% NH 3 soln 1% affording the desired product as a colourless oil (0.9g 52%).
Spectral data were consistent with the reported ones [29] . 1 
N-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)butyl]-2-nitrobenzenesulfonamide (21).
To a solution of 0.9 g (5 mmol) of 20 and Et 3 N (1.1 eq) in 20 ml of DCM cooled in an ice bath, 2-nitrobenzensulfonilchloride (1 eq) was added portionwise. The mixture was stirred at RT for 30 min, taken up with DCM and washed with 20 ml of 1N HCl; the aqueous phase was extracted with DCM (2 x 10 ml) and the organic phase was then washed with water and brine, dried over Na 2 SO 4 , filtered and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with PE/EtOAc 30% to afford the desire product as a colourless oil (1.55 g, 83% 
N-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)butyl]-N-ethyl-2-nitrobenzenesulfonamide (22).
To a stirred solution of 21 (1.55 g; 4.3 mmol) in 50 ml of DMF, K 2 CO 3 (10 eq) and EtI (1.5 eq)
were added. The solution was stirred at 60 °C for 10 hrs, taken up with 100 ml of Et 2 O and washed with water (3 x 50 ml) and brine; the organic phase was dried over Na 2 SO 4 , filtered and dried under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with PE/EtOAc 30%, to afford the desired product as a pale yellow oil (1.63 g 98% 
N-[4-(2,2-dimethyl-1,3-dioxolan-4-yl)butyl]-N-ethylamine (23).
A solution of 1.08 ml (2.5 eq) of thiophenol in 15 ml of CH 3 CN kept under N 2 was cooled in an ice bath. To this solution 0.60 g of KOH (2.5 eq) dissolved in 2ml of water were added dropwise. 
6-(ethylamino)hexane-1,2-diol (25).
ofCompound 23 (0.64 g; 3.2 mmol) was dissolved in 20 ml of 80% TFA in water. The mixture was refluxed for 24 hrs, then it was evaporated under reduced pressure. The residue was taken up with 20 ml of water and activated carbon was added; the suspension was heated to boiling and filtered through a bed of celite. The filtrate was evaporated under reduced pressure and the residue was eluted through an ion-exchange column over Amberlite IRA-400 resin to afford 0.42 g of the title product as a colourless oil (82% free base 
N-ethyl-5,6-bis(nitrooxy)hexan-1-ammonium nitrate (26).
To 20 ml of fuming nitric acid cooled at -15 °C, 25 (1.5 g; 9.3 mmol) was added dropwise over a period of 10 min The mixture was then allowed to warm to room temperature and was kept under stirring for 40 h. After that period the solvent was distilled under reduced pressure and the residue was dropped and triturated in 150 ml of dry diethyl ether at -15 °C. The white solid thus obtained was collected through filtration and washed thoroughly with dry diethyl ether to afford 1.97 g of the title compounds (67% as nitric acid salt 
General procedure for the synthesis of the derivatives 28-35.
The appropriate nitric ester and 27 (1 eq.) were suspended in a mixture of CH 3 CN/DMF 1/1. To the suspension, cooled at 0 °C, 3.5 eq. of Et 3 N were added dropwise. The mixture was kept under stirring at room temperature for 6 h. After that period the solvent was distilled under reduced pressure and the residue was taken up with water and extracted with EtOAc. The organic phase was washed with brine, dried over Na 2 SO 4 , filtered and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with mixture of DCM/MeOH to afford the desired products as yellow solids in 35 -56% yields. 
7-chloro-4-{[4-hydroxy-3-({[3-(nitrooxy)propyl]ammonio}methyl)phenyl]amino}quinolinium dihydrchloride (28).
7-chloro-4-{[3-({ethyl[3-(nitrooxy)propyl]ammonio}methyl)-4-hydroxyphenyl]amino}quinolinium dihydrochloride (29).
The free base was taken up with MeOH and HCl saturated Et 2 O was added at 0 °C; the solution was kept under stirring at room temperature for two hours, then the solvent was evaporated under reduced pressure and the solid was freeze dried to give the product as the hydrochloride. 
6-[{5-[(7-chloroquinolin-4-yl)amino]-2-hydroxybenzyl}(ethyl)amino]hexan-1,2-diyl dinitrate (31
7-chloro-4-{[4-hydroxy-3-({4-[2-(nitrooxy)ethyl]piperidinium-1-yl}methyl)phenyl]amino}quinolinium dihydrochloride (33).
7-chloro-4-{[4-hydroxy-3-({4-[2-(nitrooxy)ethyl]piperazinediium-1-yl}methyl)phenyl]amino}quinolinium trihydrochloride (34).
7-chloro-4-{[4-hydroxy-3-({4-[3-(nitrooxy)propyl]piperazinediium-1-yl}methyl)phenyl]amino}quinolinium trihydrochloride (35).
4-[(7-Chloroquinolin-4-yl)amino]-2-[ethyl-(2-hydroxyethyl)amino]methylphenol dihydrochloride (36)
To a stirred solution of 2-(ethylamino)ethanol (0.82 mL; 8.43 mmol) in CH 3 CN (20 mL), kept under nitrogen, 27 (1 g; 2.81 mmol) was added. The yellow suspension was stirred for 18 h. The solvent was evaporated and the yellow residue was treated with water (15 mL) and stirred for 15 min. The solid was collected on a buchner funnel and washed with water (50 mL). 
4-[(7-Chloroquinolin-4-yl)amino]-2-{[([2-(3-phenylsulfonylfuroxan-4-yl)oxy]ethyl}ethyl)amino]methyl}phenol dihydrochloride (40)
To a suspension of 27 (0.9 g; 2.53 mmol) in iPrOH/DMF 10/1 (16.5 mL), stirred under nitrogen at RT, triethylamine (10.1 mmol) was added. After 15 min of stirring a solution of 39 (0.7g; 3.54 mmol) in iPrOH/DMF 10/1 (10 mL) was added dropwise at RT. The reaction mixture was stirred for 24 h, the solvent evaporated under reduced pressure to leave an oily residue which was taken up with water (20 mL) and extracted with EtOAc (4 x 30 mL). 
Dissociation constants determination
The ionisation constants of compounds were determined by potentiometric titration with the 
Parasite growth and drug susceptibility assay
Compounds were dissolved in either water (chloroquine) or DMSO and then diluted with medium to achieve the required concentrations (final DMSO concentration <1 %, which is non-toxic to the parasite). Drugs were placed in 96 wells flat-bottom microplates (COSTAR) and serial dilutions made. Asynchronous cultures with parasitemia of 1-1.5 % and 1 % final haematocrit were aliquoted into the plates and incubated for 72 hours at 37 °C. Parasite growth was determined spectrophotometrically (OD 650 ) by measuring the activity of the parasite lactate dehydrogenase (pLDH), according to a modified version of Makler's method in control and drug-treated cultures [33, 34] . Antimalarial activity is expressed as the 50 % inhibitory concentrations (IC 50 ); each IC 50 value is the mean and standard deviation of at least three separate experiments.
Vasodilator activity assay.
Thoracic aortas were isolated from male Wistar rats weighing 180-200 g. The endothelium was removed and the vessels were elically cut: three strips were obtained from each aorta. Responses were recorded by an isometric transducer connected to the MacLab System PowerLab.
3.4.4.Mice, infection and treatment
Six to eight week old C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME).
All experimental protocols were reviewed and approved by LJBI Institutional Animal Care and Use
Committee. Plasmodium berghei ANKA strain expressing the green fluorescent protein (PbA-GFP, a kind donation of MR4, Manassas, VA) was inoculated intraperitoneally (1x10 6 parasitized red blood cells) and parasitemia, motor behavior, rectal temperature and weight were checked beginning on day 5 after infection. CM was defined as the presentation of one or more of the following clinical signs of neurological involvement: ataxia, limb paralysis, poor righting reflex, seizures, roll-over, coma. Additional clinical evaluation was performed using a set of six simple behavioral tests, as described [18] . Mice with late stage CM were treated with either amodiaquine (AQ) at 1mg per mouse, compound 40 or compound 31 at molar-equivalent doses (1.4mg and 1.15mg per mouse, respectively) daily for 5 days. Compound 40 was prepared in vehicle containaing 20% DMSO (Sigma, St Louis, MO), 20% polyethyleneglycol 400 (Sigma) and 60% saline, and compound 31 was prepared in saline. AQ was given in the control group in the same vehicle as the test compound. Each mouse received 100µL intraperitoneally. The EC 50 represents the M equivalents of test compounds required to relax the precontracted rat aorta strips by 50% (data are expressed as means  SE). c not able to reach 50% tissue relaxation at the maximum concentration tested. -= not tested
